林德拉雷雷迪克斯通过通过miR-33-PPARα/LXRα轴调节逆胆固醇运输来减轻超脂血症
He Ye1, Weizhi Lai2, Shanshan Lei3
1Department of Pharmacy, Zhejiang Hospital, Hangzhou, Zhejiang, 310013, China.
Endocrine, metabolic & immune disorders drug targets
|March 15, 2026
概括
林德拉雷雷迪克斯 (WY) 通过通过miR-33通路调节胆固醇运输,有效降低高脂血症. 这种天然化合物向miR-33-PPARα/LXRα轴,为管理高胆固醇提供了一种新的治疗方法.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 微RNA-33 (miR-33) 降低了参与逆胆固醇运输 (RCT) 的关键蛋白质的下调.
- 林德拉雷雷迪克斯 (WY) 通过调节RCT,表现出抗高脂效应.
- 在WY对RCT的调节中miR-33的确切作用尚待阐明.
研究的目的:
- 为了调查WY对RCT的调节是否由miR-33.3介导.
- 探索WY在管理高脂血症中的潜在分子机制.
主要方法:
- 在体内研究使用高脂血症 (HLP) 小鼠与miR-33过度表达模型.
- 在氧-LDL诱导的RAW 264.7巨细胞与操纵的miR-33水平的体外实验.
- 通过RT-qPCR,Western blotting和多重免疫光检测评估血清脂质概况,肝脂积累和与RCT相关的蛋白质表达 (ABCA1,ABCG1,PPARα,LXRα,FXR,SR-BI).
主要成果:
- 在HLP小鼠中,WY显著降低了总胆固醇 (TC),甘油三 (TG) 和LDL-C水平.
- 在体内和体外,WY治疗增加了与RCT相关的蛋白质 (ABCA1,ABCG1,PPARα,LXRα,FXR).
- 在巨细胞中减轻了WY的脂质沉积,并在细胞中增强了RCT蛋白表达,这些细胞具有过度表达和低的miR-33水平.
结论:
- 通过通过miR-33-PPARα/LXRα轴调节RCT,WY减轻了超脂血症.
- 通过WY通过miR-33抑制激活PPARα/LXRα,与他类药物或纤维化物相比,提供了一个独特的机制.
- 这种方法对他类药物不耐受患者或作为辅助治疗具有潜力.
更多相关视频
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
2.9K
09:20An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
Published on: May 4, 2021
4.4K
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management
564
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
564
Lipid Absorption
3.3K
Dietary triglycerides from chyme in the duodenum are mixed with bile salts produced by the liver to emulsify fats. As a result, large droplets are broken down into smaller ones, increasing the surface area for enzymatic action. Once emulsified, pancreatic lipases hydrolyze the triglycerides into free fatty acids and monoglycerides.
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
These breakdown products bind with bile salts and lecithin to form micelles, which quickly pass between microvilli to come in close contact with the apical...
3.3K
Cholesterol: Significance and Regulation
1.8K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.8K
Lipid Digestion
101.8K
Lipids are large molecules that are generally not water-soluble. Since most of the digestive enzymes in the human body are water-based, there are specific steps the body must take to break down lipids and make them available for use.
101.8K
